Based on the significant underperformance in the Q4 results and the worse-than-expected response rates in the tumor-agnostic trial, I believe AADI wil...
Read More
Based on the significant underperformance in the Q4 results and the worse-than-expected response rates in the tumor-agnostic trial, I believe AADI will face downward pressure. These factors make it a prime candidate for a short position in the near term.